Metastatic Colorectal Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metastatic Colorectal Cancer – Pipeline Review, H2 2016’, provides an overview of the Metastatic Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer

The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects

The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AB Science SA

AbbVie Inc

Advenchen Laboratories LLC

Alchemia Ltd

Apexigen Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Astex Pharmaceuticals Inc

AstraZeneca Plc

Bavarian Nordic A/S

Bayer AG

Biocon Ltd

Bionomics Ltd

Bionovis SA

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Burzynski Research Institute Inc

Celgene Corp

Celltrion Inc

Cipla Ltd

Coherus BioSciences Inc

Cornerstone Pharmaceuticals Inc

DanDrit Biotech A/S

Dr. Reddy's Laboratories Ltd

EirGenix Inc.

Eisai Co Ltd

Eli Lilly and Company

EnGeneIC Ltd

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

Genor BioPharma Co Ltd

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glycotope GmbH

Hemispherx Biopharma Inc

Hutchison MediPharma Ltd

Ignyta Inc

Immodulon Therapeutics Ltd

Immunomedics Inc

Immunovative Therapies Ltd

Karyopharm Therapeutics Inc

Mabion SA

Mabtech Limited

mAbxience SA

MacroGenics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Merus NV

MolMed SpA

Mologen AG

Morphotek Inc

Mycenax Biotech Inc

Natco Pharma Ltd

Nektar Therapeutics

Nippon Kayaku Co Ltd

Northwest Biotherapeutics Inc

Novartis AG

OBI Pharma Inc

Oncobiologics Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Pivot Pharmaceuticals Inc

Precision Biologics Inc

PsiOxus Therapeutics Ltd

R Pharm

Regeneron Pharmaceuticals Inc

Richter Gedeon Nyrt

Shanghai Henlius Biotech Co., Ltd.

Shire Plc

Sillajen Biotherapeutics

Symphogen A/S

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Tocagen Inc

Vaximm AG

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Metastatic Colorectal Cancer Overview 8

Therapeutics Development 9

Metastatic Colorectal Cancer - Therapeutics under Development by Companies 11

Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 18

Metastatic Colorectal Cancer - Pipeline Products Glance 19

Metastatic Colorectal Cancer - Products under Development by Companies 23

Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 32

Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 33

Metastatic Colorectal Cancer - Therapeutics Assessment 122

Drug Profiles 149

Metastatic Colorectal Cancer - Dormant Projects 682

Metastatic Colorectal Cancer - Discontinued Products 692

Metastatic Colorectal Cancer - Product Development Milestones 695

Appendix 710

List of Tables

List of Tables

Number of Products under Development for Metastatic Colorectal Cancer, H2 2016 25

Number of Products under Development for Metastatic Colorectal Cancer – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Development by Companies, H2 2016 (Contd..6) 33

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Development, H2 2016 37

Comparative Analysis by Unknown Stage Development, H2 2016 38

Products under Development by Companies, H2 2016 39

Products under Development by Companies, H2 2016 (Contd..1) 40

Products under Development by Companies, H2 2016 (Contd..2) 41

Products under Development by Companies, H2 2016 (Contd..3) 42

Products under Development by Companies, H2 2016 (Contd..4) 43

Products under Development by Companies, H2 2016 (Contd..5) 44

Products under Development by Companies, H2 2016 (Contd..6) 45

Products under Development by Companies, H2 2016 (Contd..7) 46

Products under Development by Companies, H2 2016 (Contd..8) 47

Products under Investigation by Universities/Institutes, H2 2016 48

Metastatic Colorectal Cancer – Pipeline by 3SBio Inc, H2 2016 49

Metastatic Colorectal Cancer – Pipeline by AB Science SA, H2 2016 50

Metastatic Colorectal Cancer – Pipeline by AbbVie Inc, H2 2016 51

Metastatic Colorectal Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 52

Metastatic Colorectal Cancer – Pipeline by Alchemia Ltd, H2 2016 53

Metastatic Colorectal Cancer – Pipeline by Apexigen Inc, H2 2016 54

Metastatic Colorectal Cancer – Pipeline by ArQule Inc, H2 2016 55

Metastatic Colorectal Cancer – Pipeline by Array BioPharma Inc, H2 2016 56

Metastatic Colorectal Cancer – Pipeline by Asana BioSciences LLC, H2 2016 57

Metastatic Colorectal Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 58

Metastatic Colorectal Cancer – Pipeline by AstraZeneca Plc, H2 2016 59

Metastatic Colorectal Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 60

Metastatic Colorectal Cancer – Pipeline by Bayer AG, H2 2016 61

Metastatic Colorectal Cancer – Pipeline by Biocon Ltd, H2 2016 62

Metastatic Colorectal Cancer – Pipeline by Bionomics Ltd, H2 2016 63

Metastatic Colorectal Cancer – Pipeline by Bionovis SA, H2 2016 64

Metastatic Colorectal Cancer – Pipeline by Biothera Pharmaceutical Inc, H2 2016 65

Metastatic Colorectal Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 66

Metastatic Colorectal Cancer – Pipeline by Boston Biomedical Inc, H2 2016 67

Metastatic Colorectal Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 68

Metastatic Colorectal Cancer – Pipeline by Burzynski Research Institute Inc, H2 2016 69

Metastatic Colorectal Cancer – Pipeline by Celgene Corp, H2 2016 70

Metastatic Colorectal Cancer – Pipeline by Celltrion Inc, H2 2016 71

Metastatic Colorectal Cancer – Pipeline by Cipla Ltd, H2 2016 72

Metastatic Colorectal Cancer – Pipeline by Coherus BioSciences Inc, H2 2016 73

Metastatic Colorectal Cancer – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 74

Metastatic Colorectal Cancer – Pipeline by DanDrit Biotech A/S, H2 2016 75

Metastatic Colorectal Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 76

Metastatic Colorectal Cancer – Pipeline by EirGenix Inc., H2 2016 77

Metastatic Colorectal Cancer – Pipeline by Eisai Co Ltd, H2 2016 78

Metastatic Colorectal Cancer – Pipeline by Eli Lilly and Company, H2 2016 79

Metastatic Colorectal Cancer – Pipeline by EnGeneIC Ltd, H2 2016 80

Metastatic Colorectal Cancer – Pipeline by Etubics Corp, H2 2016 81

Metastatic Colorectal Cancer – Pipeline by Exelixis Inc, H2 2016 82

Metastatic Colorectal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 83

Metastatic Colorectal Cancer – Pipeline by Gene Techno Science Co Ltd, H2 2016 84

Metastatic Colorectal Cancer – Pipeline by Genor BioPharma Co Ltd, H2 2016 85

Metastatic Colorectal Cancer – Pipeline by Genzyme Corp, H2 2016 86

Metastatic Colorectal Cancer – Pipeline by Gilead Sciences Inc, H2 2016 87

Metastatic Colorectal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 88

Metastatic Colorectal Cancer – Pipeline by Glycotope GmbH, H2 2016 89

Metastatic Colorectal Cancer – Pipeline by Hemispherx Biopharma Inc, H2 2016 90

Metastatic Colorectal Cancer – Pipeline by Hutchison MediPharma Ltd, H2 2016 91

Metastatic Colorectal Cancer – Pipeline by Ignyta Inc, H2 2016 92

Metastatic Colorectal Cancer – Pipeline by Immodulon Therapeutics Ltd, H2 2016 93

Metastatic Colorectal Cancer – Pipeline by Immunomedics Inc, H2 2016 94

Metastatic Colorectal Cancer – Pipeline by Immunovative Therapies Ltd, H2 2016 95

Metastatic Colorectal Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2016 96

Metastatic Colorectal Cancer – Pipeline by Mabion SA, H2 2016 97

Metastatic Colorectal Cancer – Pipeline by Mabtech Limited, H2 2016 98

Metastatic Colorectal Cancer – Pipeline by mAbxience SA, H2 2016 99

Metastatic Colorectal Cancer – Pipeline by MacroGenics Inc, H2 2016 100

Metastatic Colorectal Cancer – Pipeline by MedImmune LLC, H2 2016 101

Metastatic Colorectal Cancer – Pipeline by Merck & Co Inc, H2 2016 102

Metastatic Colorectal Cancer – Pipeline by Merck KGaA, H2 2016 103

Metastatic Colorectal Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 104

Metastatic Colorectal Cancer – Pipeline by Merus NV, H2 2016 105

Metastatic Colorectal Cancer – Pipeline by MolMed SpA, H2 2016 106

Metastatic Colorectal Cancer – Pipeline by Mologen AG, H2 2016 107

Metastatic Colorectal Cancer – Pipeline by Morphotek Inc, H2 2016 108

Metastatic Colorectal Cancer – Pipeline by Mycenax Biotech Inc, H2 2016 109

Metastatic Colorectal Cancer – Pipeline by Natco Pharma Ltd, H2 2016 110

Metastatic Colorectal Cancer – Pipeline by Nektar Therapeutics, H2 2016 111

Metastatic Colorectal Cancer – Pipeline by Nippon Kayaku Co Ltd, H2 2016 112

Metastatic Colorectal Cancer – Pipeline by Northwest Biotherapeutics Inc, H2 2016 113

Metastatic Colorectal Cancer – Pipeline by Novartis AG, H2 2016 114

Metastatic Colorectal Cancer – Pipeline by OBI Pharma Inc, H2 2016 115

Metastatic Colorectal Cancer – Pipeline by Oncobiologics Inc, H2 2016 116

Metastatic Colorectal Cancer – Pipeline by Oncolytics Biotech Inc, H2 2016 117

Metastatic Colorectal Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 118

Metastatic Colorectal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 119

Metastatic Colorectal Cancer – Pipeline by Pfizer Inc, H2 2016 120

Metastatic Colorectal Cancer – Pipeline by Pharma Mar SA, H2 2016 121

Metastatic Colorectal Cancer – Pipeline by Pivot Pharmaceuticals Inc, H2 2016 122

Metastatic Colorectal Cancer – Pipeline by Precision Biologics Inc, H2 2016 123

Metastatic Colorectal Cancer – Pipeline by PsiOxus Therapeutics Ltd, H2 2016 124

Metastatic Colorectal Cancer – Pipeline by R Pharm, H2 2016 125

Metastatic Colorectal Cancer – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 126

Metastatic Colorectal Cancer – Pipeline by Richter Gedeon Nyrt, H2 2016 127

Metastatic Colorectal Cancer – Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 128

Metastatic Colorectal Cancer – Pipeline by Shire Plc, H2 2016 129

Metastatic Colorectal Cancer – Pipeline by Sillajen Biotherapeutics, H2 2016 130

Metastatic Colorectal Cancer – Pipeline by Symphogen A/S, H2 2016 131

Metastatic Colorectal Cancer – Pipeline by Synermore Biologics Co Ltd, H2 2016 132

Metastatic Colorectal Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 133

Metastatic Colorectal Cancer – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2016 134

Metastatic Colorectal Cancer – Pipeline by Tocagen Inc, H2 2016 135

Metastatic Colorectal Cancer – Pipeline by Vaximm AG, H2 2016 136

Metastatic Colorectal Cancer – Pipeline by XBiotech Inc, H2 2016 137

Assessment by Monotherapy Products, H2 2016 138

Assessment by Combination Products, H2 2016 139

Number of Products by Stage and Target, H2 2016 141

Number of Products by Stage and Mechanism of Action, H2 2016 151

Number of Products by Stage and Route of Administration, H2 2016 162

Number of Products by Stage and Molecule Type, H2 2016 164

Metastatic Colorectal Cancer – Dormant Projects, H2 2016 698

Metastatic Colorectal Cancer – Dormant Projects (Contd..1), H2 2016 699

Metastatic Colorectal Cancer – Dormant Projects (Contd..2), H2 2016 700

Metastatic Colorectal Cancer – Dormant Projects (Contd..3), H2 2016 701

Metastatic Colorectal Cancer – Dormant Projects (Contd..4), H2 2016 702

Metastatic Colorectal Cancer – Dormant Projects (Contd..5), H2 2016 703

Metastatic Colorectal Cancer – Dormant Projects (Contd..6), H2 2016 704

Metastatic Colorectal Cancer – Dormant Projects (Contd..7), H2 2016 705

Metastatic Colorectal Cancer – Dormant Projects (Contd..8), H2 2016 706

Metastatic Colorectal Cancer – Dormant Projects (Contd..9), H2 2016 707

Metastatic Colorectal Cancer – Discontinued Products, H2 2016 708

Metastatic Colorectal Cancer – Discontinued Products (Contd..1), H2 2016 709

Metastatic Colorectal Cancer – Discontinued Products (Contd..2), H2 2016 710

List of Figures

List of Figures

Number of Products under Development for Metastatic Colorectal Cancer, H2 2016 25

Number of Products under Development for Metastatic Colorectal Cancer – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Products, H2 2016 37

Assessment by Monotherapy Products, H2 2016 138

Assessment by Combination Products, H2 2016 139

Number of Products by Top 10 Targets, H2 2016 140

Number of Products by Stage and Top 10 Targets, H2 2016 140

Number of Products by Top 10 Mechanism of Actions, H2 2016 150

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 150

Number of Products by Top 10 Routes of Administration, H2 2016 161

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161

Number of Products by Top 10 Molecule Types, H2 2016 163

Number of Products by Stage and Top 10 Molecule Types, H2 2016 163

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports